These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32193838)

  • 21. Novel Immunotherapy Combinations.
    Bashir B; Wilson MA
    Curr Oncol Rep; 2019 Nov; 21(11):96. PubMed ID: 31696332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Targets for the Treatment of Melanoma.
    Ambrosi L; Khan S; Carvajal RD; Yang J
    Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
    Georganaki M; van Hooren L; Dimberg A
    Front Immunol; 2018; 9():3081. PubMed ID: 30627131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer.
    Shevchenko I; Bazhin AV
    Front Immunol; 2018; 9():1816. PubMed ID: 30131808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
    Wong RL; Yu EY
    Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers.
    Ferriss JS; Williams-Brown MY
    Curr Treat Options Oncol; 2019 Aug; 20(10):75. PubMed ID: 31444655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading.
    Force J; Leal JHS; McArthur HL
    Curr Treat Options Oncol; 2019 Mar; 20(4):35. PubMed ID: 30923913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
    Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
    J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
    Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status of immunotherapy for gastrointestinal stromal tumor.
    Tan Y; Trent JC; Wilky BA; Kerr DA; Rosenberg AE
    Cancer Gene Ther; 2017 Mar; 24(3):130-133. PubMed ID: 28186088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
    Vigano S; Alatzoglou D; Irving M; Ménétrier-Caux C; Caux C; Romero P; Coukos G
    Front Immunol; 2019; 10():925. PubMed ID: 31244820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy in aggressive B-cell lymphomas.
    Jacobson CA; Armand P
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):299-305. PubMed ID: 30213400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
    Gide TN; Wilmott JS; Scolyer RA; Long GV
    Clin Cancer Res; 2018 Mar; 24(6):1260-1270. PubMed ID: 29127120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTEN Mutations Trigger Resistance to Immunotherapy.
    Cheng F; Eng C
    Trends Mol Med; 2019 Jun; 25(6):461-463. PubMed ID: 30928438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired resistance to cancer immunotherapy.
    Draghi A; Chamberlain CA; Furness A; Donia M
    Semin Immunopathol; 2019 Jan; 41(1):31-40. PubMed ID: 29968044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.
    Tun AM; Ansell SM
    Cancer Treat Rev; 2020 Aug; 88():102042. PubMed ID: 32521386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.